Mirati Therapeutics Inc (NASDAQ:MRTX) major shareholder Boxer Capital, Llc sold 425,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $69.00, for a total value of $29,325,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Boxer Capital, Llc also recently made the following trade(s):
- On Thursday, January 17th, Boxer Capital, Llc purchased 150,000 shares of Mirati Therapeutics stock. The stock was acquired at an average cost of $62.00 per share, with a total value of $9,300,000.00.
- On Tuesday, January 8th, Boxer Capital, Llc sold 550,000 shares of Mirati Therapeutics stock. The stock was sold at an average price of $52.10, for a total value of $28,655,000.00.
Shares of NASDAQ:MRTX traded down $0.74 during trading on Tuesday, hitting $72.19. The stock had a trading volume of 862,517 shares, compared to its average volume of 724,550. Mirati Therapeutics Inc has a 12-month low of $24.65 and a 12-month high of $79.31. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of -22.63 and a beta of 2.14.
Several large investors have recently made changes to their positions in MRTX. FMR LLC raised its stake in shares of Mirati Therapeutics by 67.5% in the second quarter. FMR LLC now owns 1,986,315 shares of the biotechnology company’s stock worth $97,926,000 after purchasing an additional 800,223 shares during the last quarter. BlackRock Inc. raised its position in Mirati Therapeutics by 30.0% during the fourth quarter. BlackRock Inc. now owns 2,052,949 shares of the biotechnology company’s stock valued at $87,086,000 after acquiring an additional 474,097 shares in the last quarter. Credit Suisse AG raised its position in Mirati Therapeutics by 1,682.9% during the third quarter. Credit Suisse AG now owns 449,408 shares of the biotechnology company’s stock valued at $21,167,000 after acquiring an additional 424,202 shares in the last quarter. Jennison Associates LLC raised its position in Mirati Therapeutics by 62.4% during the third quarter. Jennison Associates LLC now owns 998,504 shares of the biotechnology company’s stock valued at $47,030,000 after acquiring an additional 383,785 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in Mirati Therapeutics by 54.9% during the third quarter. Janus Henderson Group PLC now owns 1,025,767 shares of the biotechnology company’s stock valued at $48,314,000 after acquiring an additional 363,728 shares in the last quarter.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.
Recommended Story: Lock-Up Period Expiration
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.